Kura Oncology’s (KURA) Overweight Rating Reiterated at Cantor Fitzgerald

Kura Oncology (NASDAQ:KURA)‘s stock had its “overweight” rating reiterated by investment analysts at Cantor Fitzgerald in a note issued to investors on Thursday,Benzinga reports.

Several other equities analysts have also recently issued reports on the company. HC Wainwright lifted their price objective on Kura Oncology from $32.00 to $37.00 and gave the company a “buy” rating in a research note on Thursday. Wedbush reiterated an “outperform” rating and set a $37.00 price target on shares of Kura Oncology in a report on Monday, November 4th. UBS Group started coverage on shares of Kura Oncology in a report on Thursday, October 24th. They issued a “buy” rating and a $27.00 price objective on the stock. Stifel Nicolaus downgraded shares of Kura Oncology from a “buy” rating to a “hold” rating and lowered their target price for the stock from $26.00 to $19.00 in a research note on Monday, October 14th. Finally, StockNews.com lowered Kura Oncology from a “hold” rating to a “sell” rating in a report on Wednesday. One investment analyst has rated the stock with a sell rating, one has given a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $29.38.

Kura Oncology Trading Up 7.4 %

NASDAQ:KURA opened at $10.80 on Thursday. Kura Oncology has a 12-month low of $9.06 and a 12-month high of $24.17. The firm has a market cap of $839.85 million, a PE ratio of -4.66 and a beta of 0.86. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. The stock has a fifty day moving average price of $18.08 and a 200 day moving average price of $19.76.

Hedge Funds Weigh In On Kura Oncology

Hedge funds have recently made changes to their positions in the company. nVerses Capital LLC acquired a new stake in shares of Kura Oncology in the 3rd quarter valued at about $25,000. SG Americas Securities LLC purchased a new stake in Kura Oncology in the first quarter valued at approximately $110,000. Point72 DIFC Ltd acquired a new stake in shares of Kura Oncology in the third quarter valued at approximately $146,000. Quarry LP purchased a new position in shares of Kura Oncology during the second quarter worth approximately $196,000. Finally, Erste Asset Management GmbH acquired a new position in shares of Kura Oncology in the 3rd quarter valued at $215,000.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.